Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
14 pending office actions • 8 art units • 14 examiners • 0 of 14 (0%) have an AI response strategy ready • 14 patents granted in the last 365 days
CUREVAC SE currently manages 15 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 15 distinct examiners, indicating that every single pending matter is being reviewed by a different individual. The portfolio is active across 8 distinct art units.
JOSEPH PAUL MIANO is the busiest examiner, though he is only responsible for 1 pending office action. This reflects a perfectly balanced distribution of work, where each of the 15 distinct examiners handles exactly one of the 15 pending office actions. The presence of 8 distinct art units suggests a broad technical range within the Biotechnology & Pharmaceuticals sector. Practitioners face a highly decentralized prosecution environment with 15 different examiners to manage.
While the 8 distinct art units provide some organizational structure, the lack of examiner overlap means that strategies must be tailored to 15 individual sets of preferences. The fact that JOSEPH PAUL MIANO handles only 1 pending office action highlights the extreme breadth of the company's current examination landscape. This structure requires significant resources to track 15 unique examiner behaviors across 8 different art units.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (14%) |
| §103 only | 5 (36%) |
| §102 only | 1 (7%) |
| Double-patenting only | 1 (7%) |
| Multi-statute (no §101) | 5 (36%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MIANO, JOSEPH PAUL | 1 | 36.0% | +63.3% |
| HOERNER, PAUL ELLSWORTH | 1 | 50.0% | +62.1% |
| MCLEOD, AFRICA MHAIRIE | 1 | 51.9% | +67.5% |
| BERTOGLIO, VALARIE E | 1 | 64.1% | +30.2% |
| RAHMAN, MASUDUR | 1 | 72.7% | +31.7% |
| RYAN, DOUGLAS CHARLES | 1 | 39.2% | +47.6% |
| CHEN, STACY BROWN | 1 | 66.1% | +40.6% |
| SULLIVAN, STEPHANIE LAUREN | 1 | 58.1% | +40.9% |
| GRAY, JESSICA | 1 | 0.0% | +0.0% |
| SHIN, DANA H | 1 | 27.0% | +27.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18183082 | RNA ENCODING A TUMOR ANTIGEN | SHIN, DANA H | 58d overdue |
| 18415477 | ARTIFICIAL NUCLEIC ACID MOLECULES | BERTOGLIO, VALARIE E | 11d overdue |
| 18705499 | IMPROVED CIRCULAR RNA FOR EXPRESSING THERAPEUTIC PROTEINS | MIANO, JOSEPH PAUL | — |
| 18688749 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | HOERNER, PAUL ELLSWORTH | — |
| 18558531 | IMPROVED NUCLEIC ACID SEQUENCE FOR CELL TYPE SPECIFIC EXPRESSION | RAHMAN, MASUDUR | — |
| 18283601 | IMMUNOGENIC COMPOSITIONS | CHEN, STACY BROWN | — |
| 18320187 | ARTIFICIAL NUCLEIC ACID MOLECULES | GRAY, JESSICA | — |
| 18043317 | MULTIVALENT NUCLEIC ACID BASED CORONAVIRUS VACCINES | JADHAO, SAMADHAN JAISING | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18183082 | RNA ENCODING A TUMOR ANTIGEN | SHIN, DANA H | 58d overdue |
| 18415477 | ARTIFICIAL NUCLEIC ACID MOLECULES | BERTOGLIO, VALARIE E | 11d overdue |
| 18553531 | SYRINGES CONTAINING PHARMACEUTICAL COMPOSITIONS COMPRISING RNA | RYAN, DOUGLAS CHARLES | 12d |
| 18320598 | RNA SEQUENCE ADAPTATION | SULLIVAN, STEPHANIE LAUREN | 62d |
| 18705499 | IMPROVED CIRCULAR RNA FOR EXPRESSING THERAPEUTIC PROTEINS | MIANO, JOSEPH PAUL | — |
| 18688749 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | HOERNER, PAUL ELLSWORTH | — |
| 18293593 | CAP ANALOGS HAVING AN ACYCLIC LINKER TO THE GUANINE DERIVATIVE NUCLEOBASE | MCLEOD, AFRICA MHAIRIE | — |
| 18558531 | IMPROVED NUCLEIC ACID SEQUENCE FOR CELL TYPE SPECIFIC EXPRESSION | RAHMAN, MASUDUR | — |
| Art Unit | Apps |
|---|---|
| 1635 | 3 |
| 1672 | 2 |
| 1637 | 2 |
| 1611 | 1 |
| 1632 | 1 |
| 1633 | 1 |
| 1682 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18705499 | IMPROVED CIRCULAR RNA FOR EXPRESSING THERAPEUTIC PROTEINS | MIANO, JOSEPH PAUL | — | §102§103 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18688749 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS | HOERNER, PAUL ELLSWORTH | 1611 | §102§103 | Non-Final OA | — | Pending | Mar 01, 2024 |
| 18293593 | CAP ANALOGS HAVING AN ACYCLIC LINKER TO THE GUANINE DERIVATIVE NUCLEOBASE | MCLEOD, AFRICA MHAIRIE | — | §102 | Non-Final OA | — | Pending | Jan 30, 2024 |
| 18415477 | ARTIFICIAL NUCLEIC ACID MOLECULES | BERTOGLIO, VALARIE E | 1632 | §103§112 | Non-Final OA | 11d overdue | Pending | Jan 17, 2024 |
| 18558531 | IMPROVED NUCLEIC ACID SEQUENCE FOR CELL TYPE SPECIFIC EXPRESSION | RAHMAN, MASUDUR | 1633 | §101§102§103 | Non-Final OA | — | Pending | Nov 01, 2023 |
| 18553531 | SYRINGES CONTAINING PHARMACEUTICAL COMPOSITIONS COMPRISING RNA | RYAN, DOUGLAS CHARLES | 1635 | §103 | Final Rejection | 12d | Pending | Sep 29, 2023 |
| 18283601 | IMMUNOGENIC COMPOSITIONS | CHEN, STACY BROWN | 1672 | §101§102DP | Non-Final OA | — | Pending | Sep 22, 2023 |
| 18320598 | RNA SEQUENCE ADAPTATION | SULLIVAN, STEPHANIE LAUREN | 1635 | §103 | Final Rejection | 62d | Pending | May 19, 2023 |
| 18320187 | ARTIFICIAL NUCLEIC ACID MOLECULES | GRAY, JESSICA | 1682 | §102§103§112 | Non-Final OA | — | Pending | May 18, 2023 |
| 18183082 | RNA ENCODING A TUMOR ANTIGEN | SHIN, DANA H | 1635 | DP | Final Rejection | 58d overdue | Pending | Mar 13, 2023 |
| 18043317 | MULTIVALENT NUCLEIC ACID BASED CORONAVIRUS VACCINES | JADHAO, SAMADHAN JAISING | 1672 | §102§103§112 | Non-Final OA | — | Pending | Feb 27, 2023 |
| 18007468 | NUCLEIC ACID ENCODED ANTIBODY MIXTURES | HAM, JIEUN | 1643 | §103 | Final Rejection | 93d overdue | Pending | Jan 30, 2023 |
| 17199120 | TARGETS FOR RNA THERAPEUTICS | MCKILLOP, JOHN CHARLES | 1637 | §103 | Non-Final OA | — | Pending | Mar 11, 2021 |
| 17045236 | NOVEL YELLOW FEVER NUCLEIC ACID MOLECULES FOR VACCINATION | VYAS, KEYUR ANILKUMAR | 1637 | §103 | Final Rejection | 72d overdue | Pending | Oct 05, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial